About
DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries. DEINOVE has developed a unique and comprehensive expertise in the...
DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries. DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe. DEINOVE is organized around two areas of expertise: ANTIBIOTICS, Next--generation anti-infectives: DEINOVE is preparing to enter a first antibiotic candidate into Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance). BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: DEINOVE already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). It also runs a program in animal nutrition with Groupe Avril. Several other partnerships are also being developed. Within the Euromedecine science park located in Montpellier, DEINOVE employs 62 employees, mainly researchers, engineers, and technicians, and has filed more than 260 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.

Executive Management :

Mr. Emmanuel Petiot ( Chief Executive Officer )
Mr. Dominique le Beller ( CEO of DEINOBIOTICS )
Mrs. Marie Bezenger ( Director of Operations )
Mr. Julien Coste ( Director of Finance & Administration )
Mr. Sébastien Enault ( Head of Business Development )
Dr. Georges Gaudriault ( Director of Research & Development )
Mrs. Coralie Martin ( Head of Communications and Investor Relations )

Board of Directors :

Dr. Philippe Pouletty ( Co-Founder, Chairman of the Board of Directors )
Prof. Miroslav Radman ( Co-Founder, Member of the Scientific Advisory Board )
Dr. Charles Woller ( Chairman, Independent Director )
Dr. Hervé Brailly ( Independent Director )
Mr. Michael Carlos ( Independent Director )
Mr. Bernard Fanget ( Independent Director )
Dr. Vincent Jarlier ( Independent Director )
Mr. Christian Pierret ( Company representative, Truffle Capital )
Dr. Yannick Plétan ( Independent Director )
Dr. Jacqueline Lecourtier ( President of the Scientific Advisory Board )
Dr. Jacques Biton ( Vice President of the Scientific Advisory Board )
Prof. Armel Guyonvarch ( Member of the Scientific Advisory Board )
Prof. Gérard Goma ( Member of the Scientific Advisory Board )
Dr. François Kepes ( Member of the Scientific Advisory Board )
Prof. Kritiina Kruus ( Member of the Scientific Advisory Board )
Dr. Ivan Matic ( Member of the Scientific Advisory Board )
Prof. Pierre Monsan ( Member of the Scientific Advisory Board )
Dr. Juha-Pekka Pitkänen ( Member of the Scientific Advisory Board )
Prof. Lesley Putman ( Member of the Scientific Advisory Board )
Mr. Serge Ratton ( Member of the Scientific Advisory Board )
Dr. Alison Robey ( Member of the Scientific Advisory Board )